Cerebral venous thrombosis (CVT) has been reported as a rare adverse event associated with COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT). Diana Aguiar de Sousa, MD, PhD, Lisbon Central University Hospital Center, University of Lisbon, Lisbon, Portugal, discusses what we know about these rare cases of CVT after vaccination against SARS-CoV-2 infection. Data from the CVT after SARS-CoV-2 vaccination registry was used to identify more than 100 cases of VITT-related CVT. The presence of platelet factor 4 (PF4) antibodies in several of these patients led to suggestions that the underlying mechanisms were similar to those behind heparin-induced thrombocytopenia. CVT cases occurring after vaccination were typically severe in presentation, often presenting with brain hemorrhagic lesions and intracranial hypertension with brain herniation, and fatality rates are reported to be significantly higher than those in patients with CVT in the pre-pandemic era. Research is ongoing to understand the underlying mechanisms and treatment strategies. This interview took place at European Stroke Organisation Conference 2022 in Lyon, France.

свернуть